A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amoxicillin and Clavulanate (AUGMENTIN ES-600)

beta Lactamase Inhibitor class · 8 generic manufacturers · 42 ANDAs filed at FDA.

First FDA approval1990-10-22
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.049/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.056
Across all dosage forms in distribution.
Highest NADAC
$0.061
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Amoxicillin and Clavulanate used for?

Amoxicillin and Clavulanate is a beta Lactamase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Amoxicillin and Clavulanate?

Yes. 42 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Amoxicillin and Clavulanate?

Across 329 Part D plans, Amoxicillin and Clavulanate averages $0.056/unit (NADAC). Lowest available: $0.049/unit. Highest in distribution: $0.061/unit.

Is Amoxicillin and Clavulanate on the FDA shortage list?

No. Amoxicillin and Clavulanate is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

beta Lactamase Inhibitor2 alternatives in D1
01
Aztreonam and Avibactam
Brand: EMBLAVEO
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Meropenem-Vaborbactam
Brand: VABOMERE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.